Por favor, use este identificador para citar o enlazar este ítem: https://hdl.handle.net/10495/38828
Registro completo de metadatos
Campo DC Valor Lengua/Idioma
dc.contributor.authorAmariles Muñoz, Pedro-
dc.contributor.authorSalazar Ospina, Andrea-
dc.contributor.authorHincapié García, Jaime Alejandro-
dc.contributor.authorGonzález Avendaño, John Sebastián-
dc.date.accessioned2024-03-27T19:47:43Z-
dc.date.available2024-03-27T19:47:43Z-
dc.date.issued2020-
dc.identifier.citationSalazar-Ospina A, Amariles P, Hincapié-García JA, González-Avendaño S. Long-term impact of pharmacist intervention in patients with bipolar disorder: extended follow-up to the EMDADER-TAB study. Heliyon. 2020 Feb 11;6(2):e03333. doi: 10.1016/j.heliyon.2020.e03333.spa
dc.identifier.urihttps://hdl.handle.net/10495/38828-
dc.description.abstractABSTRACT: Background: Pharmaceutical care (PC) through the Dader method (DMet) vs. the usual care process (UCP) significantly reduced psychiatric hospitalizations and emergency service consultations during one year of followup of outpatients with bipolar I disorder (BD-I). To date, the effect of long-term PC on the use of health services by BD-I patients once pharmacist intervention has ended is unknown. Objective: To determine whether the effect of PC measured by the decrease in psychiatric hospitalizations and emergency service consultations is maintained one year after pharmacist intervention ceases. Methods: This was a retrospective analysis of patients who had previously participated in a randomized, controlled, prospective, single-center clinical trial to compare PC (intervention group) vs. UCP (control group) in BD-I patients. Data were collected from November 2012 to March 2014. The primary outcome was the use of health services measured by the number of psychiatric hospitalizations and emergency service consultations. Descriptive statistics, Student's t-test, Kaplan–Meier function, and Log-Rank test were used. Results: The study included 92 patients: 43 in the intervention group and 49 in the control group. Eleven psychiatric hospitalizations occurred for the intervention group and 19 for the control group. One year after pharmacist intervention ceased, there were no significant differences between the groups in psychiatric hospitalizations (p ¼ 0.261). There were 14 emergency service consultations for the intervention group, and 24 for the control group without significant differences (p ¼ 0.212). Conclusions: PC through the DMet has no long-term effects on psychiatric hospitalizations and emergency department consultations in patients with BD-I following discontinuation of pharmacist intervention; the effect dissipates when the intervention ceases. Future studies should focus efforts on identifying factors associated with PC that explain why the outcomes derived from this intervention are not maintained in the long term.spa
dc.format.extent5 páginasspa
dc.format.mimetypeapplication/pdfspa
dc.language.isoengspa
dc.publisherElsevierspa
dc.type.hasversioninfo:eu-repo/semantics/publishedVersionspa
dc.rightsinfo:eu-repo/semantics/openAccessspa
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/2.5/co/*
dc.titleLong-term impact of pharmacist intervention in patients with bipolar disorder: extended follow-up to the EMDADER-TAB studyspa
dc.typeinfo:eu-repo/semantics/articlespa
dc.publisher.groupGrupo de Investigación de Tecnología en Regencia de Farmaciaspa
dc.publisher.groupPromoción y Prevención Farmacéuticaspa
dc.identifier.doi10.1016/j.heliyon.2020.e03333-
oaire.versionhttp://purl.org/coar/version/c_970fb48d4fbd8a85spa
dc.rights.accessrightshttp://purl.org/coar/access_right/c_abf2spa
dc.identifier.eissn2405-8440-
oaire.citationtitleHeliyonspa
oaire.citationstartpage1spa
oaire.citationendpage5spa
oaire.citationvolume6spa
oaire.citationissue2spa
dc.rights.creativecommonshttps://creativecommons.org/licenses/by-nc-nd/4.0/spa
oaire.fundernameUniversidad de Antioquia. Vicerrectoría de investigación. Comité para el Desarrollo de la Investigación - CODIspa
oaire.fundernameColombia. Ministerio de Ciencia Tecnología e Innovación - Minicienciasspa
dc.publisher.placeLondres, Inglaterraspa
dc.type.coarhttp://purl.org/coar/resource_type/c_2df8fbb1spa
dc.type.redcolhttps://purl.org/redcol/resource_type/ARTspa
dc.type.localArtículo de investigaciónspa
dc.subject.decsPsiquiatría-
dc.subject.decsPsychiatry-
dc.subject.decsFarmacología-
dc.subject.decsPharmacology-
dc.subject.decsTrastornos Mentales-
dc.subject.decsMental Disorders-
dc.subject.decsPsicofarmacología-
dc.subject.decsPsychopharmacology-
dc.subject.decsServicios Farmacéuticos-
dc.subject.decsPharmaceutical Services-
dc.subject.decsTrastorno Bipolar-
dc.subject.decsBipolar Disorder-
dc.subject.decsHospitalización-
dc.subject.decsHospitalization-
dc.subject.decsServicios de Urgencia Psiquiátrica-
dc.subject.decsEmergency Services, Psychiatric-
dc.description.researchgroupidCOL0135121spa
dc.description.researchgroupidCOL0074661spa
oaire.awardnumber2018-2019spa
oaire.awardnumber528spa
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D011570-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D010600-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D001523-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D011600-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D010593-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D001714-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D006760-
dc.subject.meshurihttps://id.nlm.nih.gov/mesh/D004637-
dc.relation.ispartofjournalabbrevHeliyonspa
oaire.funderidentifier.rorRoR:03bp5hc83-
oaire.funderidentifier.rorRoR:03fd5ne08-
Aparece en las colecciones: Artículos de Revista en Farmacéutica y Alimentarias

Ficheros en este ítem:
Fichero Descripción Tamaño Formato  
AmarilesPedro_2020_Long-Term_Impact_Pharmacist_Intervention.pdfArtículo de investigación395.69 kBAdobe PDFVisualizar/Abrir


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons